57370-13-5 Usage
General Description
2,6-BIS(2-HYDROXYETHYLAMINO)-4,8-DIPIPERIDINOPYRIMIDO(5,4-D)PYRIMIDINEDIPYRIDAMOLE, also known as dipyridamole, is a medication that works by preventing the formation of blood clots, thus reducing the risk of stroke or heart attack. It belongs to a class of drugs called antiplatelet agents and works by inhibiting the activity of platelets, which are involved in the formation of blood clots. Dipyridamole is often used in combination with other medications, such as aspirin, to further reduce the risk of blood clots in patients who have had cardiac stents or heart valve replacements. It can also be used in the diagnosis of coronary artery disease, as it is sometimes combined with a stress test to evaluate blood flow to the heart. Dipyridamole is available in tablet and injectable forms and is typically taken multiple times daily, as directed by a healthcare provider.
Check Digit Verification of cas no
The CAS Registry Mumber 57370-13-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,7,3,7 and 0 respectively; the second part has 2 digits, 1 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 57370-13:
(7*5)+(6*7)+(5*3)+(4*7)+(3*0)+(2*1)+(1*3)=125
125 % 10 = 5
So 57370-13-5 is a valid CAS Registry Number.
57370-13-5Relevant articles and documents
Synthesis, flow cytometric evaluation, and identification of highly potent dipyridamole analogues as equilibrative nucleoside transporter 1 inhibitors
Lin, Wenwei,Buolamwini, John K.
, p. 3906 - 3920 (2008/02/11)
Dipyridamole (Persantine) is a clinically used vasodilator with equilibrative nucleoside transporters 1 and 2 (ENT1 and ENT2) inhibitory activity albeit less potent than the prototype ENT1 inhibitor nitrobenzylmercaptopurine riboside (NBMPR). Dipyridamole is a good candidate for further exploration because it is a non-nucleoside and has a proven record of safe use in humans. A series of dipyridamole analogues were synthesized with systematic modification and evaluated as ENT1 inhibitors by flow cytometry. Compounds with much higher potency were identified, the best being 2,6-bis(diethanolamino)-4,8-diheptamethyleneiminopyrimido[5,4-d]pyrimidine (13) with a Ki of 0.49 nM compared to a Ki of 308 nM for dipyridamole. Compound 13 is similar in potency to the prototype potent ENT1 inhibitor NBMPR (0.43 nM). For the first time, a dipyridamole analogue has been identified that is equipotent with NBMPR. The SAR indicated that diethanolamine substituted analogues were more active than monoethanolamine compounds. Also, free hydroxyl groups are not essential for activity.
